Outcome
    Moderate Evidence

    Probiotics for Immune Function

    Probiotics modestly reduce the incidence and duration of upper respiratory tract infections in meta-analysis. Effects are strain-specific and small, so results from one product do not transfer to another.

    Overview

    Probiotics modestly reduce the incidence and duration of upper respiratory tract infections in meta-analysis. Effects are strain-specific and small, so results from one product do not transfer to another.

    Verdict

    Mixed evidence

    How It Works

    Roughly 70% of immune tissue is associated with the gut, and commensal organisms continuously shape it. Specific probiotic strains promote secretory IgA production, stimulate regulatory T cells and increase natural killer cell activity, providing a route from the gut lumen to systemic immune competence. Probiotics also strengthen the intestinal barrier by upregulating tight junction proteins and competitively excluding pathogens. These effects are organism-specific: the immunological signature of Lactobacillus rhamnosus GG differs from that of Bifidobacterium lactis, which is why strain identity, not simply CFU count, determines what a product can be expected to do.

    Dosing & Protocol

    Typical dose

    Recommended dose
    10-20 billion CFU/day taken continuously; respiratory infection trials ran 3-6 months
    Expected timeframe
    3-6 months

    Protocol

    form
    Lactobacillus rhamnosus GG, Lactobacillus casei Shirota, Bifidobacterium animalis subsp. lactis BB-12 and multi-strain products have immune-outcome trial data
    duration
    3-6 months across a season
    co factor
    Take with food. Evidence is mixed. The gut hosts around 70% of immune tissue, and probiotics measurably modulate secretory IgA, cytokine profiles, natural killer cell activity and dendritic cell signalling in trials. Clinically, a Cochrane review found probiotics modestly reduce the incidence and duration of upper respiratory tract infections and antibiotic use, though it rated the evidence low quality with substantial heterogeneity. Vaccine response studies show inconsistent enhancement. Immune support is not a measurable endpoint, so what can be said is narrow: modest reductions in specific infection outcomes with specific strains, not general immune strengthening.
    titration
    Up to 20 billion CFU/day; continuity of use matters more than dose
    starting dose
    10 billion CFU/day with food, continuously

    Evidence

    What the studies say

    A Cochrane review of probiotics for preventing acute upper respiratory tract infections found that probiotics reduced the number of participants experiencing episodes and modestly shortened episode duration compared with placebo, though the evidence was graded low quality. Trials in older adults and in children in daycare settings show similar directional benefit. Heterogeneity is the defining problem: trials use different strains, doses, durations and populations, and many are industry-funded. There is no established generic probiotic immune effect. Probiotics are generally safe in healthy people but should be used cautiously in the immunocompromised and in critically ill patients, where rare invasive infections have been reported.

    Probiotics for preventing acute otitis media in children

    Score: 8/10
    2019
    systematic_review
    n=3488

    Scott AM, Clark J, Julien B +5 more

    Probiotics may reduce the proportion of children experiencing acute otitis media.

    View source

    Probiotics for preventing acute upper respiratory tract infections

    Score: 8/10
    2015
    systematic_review
    n=3720

    Hao Q, Dong BR, Wu T

    Probiotics were better than placebo in reducing the number of participants experiencing episodes of acute upper respiratory tract infection.

    View source

    Administration of a probiotic with peanut oral immunotherapy: a randomized trial

    Score: 7/10
    2015
    rct
    n=62

    Tang ML, Ponsonby AL, Orsini F +4 more

    Lactobacillus rhamnosus combined with oral immunotherapy was associated with sustained unresponsiveness to peanut.

    View source

    Safety

    Caveats

    Immune support is a marketing frame rather than a clinical outcome, and a stronger immune system is not universally desirable - autoimmune disease is immune overactivity. Vaccination, sleep, not smoking, physical activity and handwashing have the real evidence for infection prevention. The critical safety point is a paradox: the people most drawn to immune supplements include the immunocompromised, and probiotics are precisely contraindicated there. Live organisms have caused bacteraemia and fungaemia - avoid in severe immunocompromise, neutropenia, chemotherapy, critical illness, central venous catheters, short bowel syndrome and damaged heart valves unless a specialist advises. Recurrent, severe or unusual infections warrant medical assessment for underlying immunodeficiency, HIV or diabetes rather than self-treatment. If taking immunosuppressant medication, do not add probiotics without discussing it. Mild bloating and gas in the first days are common. In pregnancy, common Lactobacillus and Bifidobacterium strains are generally regarded as safe.

    Less likely to help if

    Immunocompromised people, in whom probiotics carry infection risk rather than benefit.

    Medical Disclaimer

    The information provided on this website is for educational and informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or before starting any supplement regimen.

    Individual results may vary. The statements on this website have not been evaluated by the Food and Drug Administration. Products and information are not intended to diagnose, treat, cure, or prevent any disease.